Octanoylcarnitine
Octanoylcarnitine is an orally active medium-chain acylcarnitine transport intermediate in fatty acid β-oxidation. Octanoylcarnitine is converted to octanoyl-CoA by carnitine acetyltransferase (CrAT), which then generates energy via β-oxidation in mitochondria of the heart and skeletal muscle. Octanoylcarnitine enhances grip strength and treadmill endurance, alleviates lactic acidosis, distributes in muscle and heart tissues, increases free carnitine levels, and mitigates mitochondrial stress. Octanoylcarnitine is associated with long-chain fatty acid metabolism, shows a positive correlation with subcutaneous fat area in patients with metastatic pancreatic ductal adenocarcinoma, and is closely related to central retinal artery occlusion (CRAO).
For research use only. We do not sell to patients.
- CAS No.: 3671-77-0
- Formula: C15H29NO4
- Molecular Weight:287.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Endogenous Metabolite Isoforms
More
Biological Activity
Octanoylcarnitine (50 μM) maintains robust respiration to generate energy in isolated wild-type mouse skeletal muscle mitochondria[1].
Octanoylcarnitine (25 μM; 1 min) can be converted to octanoyl-CoA by recombinant human CrAT and CPT2 in vitro, exhibiting enzymatic activity[1].
Octanoylcarnitine (50 μM; 1 h) is efficiently converted to octanoyl-CoA by homogenates of wild-type mouse skeletal muscle and heart after incubation at 37℃[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Octanoylcarnitine (0.5 mg/g; i.g.; single administration) significantly improves treadmill exercise capacity and grip strength in muscle-specific CPT2-deficient mice[1].
Octanoylcarnitine (0.5 mg/g; i.g.; single administration) is rapidly metabolized to CO2 in healthy mice, and the metabolite is detectable in exhaled breath within 10 min[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Long-Chain Acyl-CoA Dehydrogenase Knockout (LCAD-KO) (male, 12-16 weeks, LC-FAOD model)[1]
-
Dosage:0.5 mg/g (exercise testing); 3% w/w (chronic feeding)
-
Administration:i.g.; single dose, 20 minutes prior to exercise testing; i.g.; mixed into powdered diet, ad libitum for 10 days
-
Result:Significantly increased treadmill running distance compared to vehicle control.
Significantly reduced post-run blood lactate levels compared to vehicle control.
Did not alter serum levels of diagnostic long-chain acylcarnitine C14:1-carnitine.
Increased serum levels of downstream short-chain acylcarnitines (C8, C6, C4, C2, free carnitine) to normal or above-normal levels.
Significantly increased free carnitine levels in liver, heart, and muscle.
Significantly increased octanoylcarnitine levels in liver and muscle.
-
Animal Model:muscle-specific Carnitine Palmitoyltransferase 2 Knockout (CPT2ᵐᴷᴼ) (male, LC-FAOD model)[1]
-
Dosage:0.5 mg/g
-
Administration:i.g.; single dose, 20 minutes prior to functional testing
-
Result:Significantly increased treadmill top speed compared to vehicle control.
Significantly increased grip strength compared to vehicle control.
Chemical Information
-
CAS No. 3671-77-0
-
Molecular Weight 287.40
-
Formula C15H29NO4
-
SMILES
O=C([O-])CC(OC(=O)CCCCCCC)C[N+](C)(C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Solo KJ, et al. Oral octanoylcarnitine alleviates exercise intolerance in mouse models of long-chain fatty acid oxidation disorders. JCI Insight. 2025;10(22):e199443. Published 2025 Oct 16. [Content Brief]
[2]. Gunchick V, et al. Morphomics, Survival, and Metabolites in Patients With Metastatic Pancreatic Cancer. JAMA Netw Open. 2024;7(10):e2440047. Published 2024 Oct 1. [Content Brief]
[3]. Wang C, et al. Plasmalogens and Octanoylcarnitine Serve as Early Warnings for Central Retinal Artery Occlusion. Mol Neurobiol. 2024;61(10):8026-8037. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Octanoylcarnitine Related Classifications
HY-156184 Related Classifications
Powered by Bioz
- Octanoylcarnitine
- 3671-77-0
- Endogenous Metabolite
- central retinal artery occlusion
- LCAD-KO mice
- muscle-specific CPT2-deficient mice
- carnitine acetyltransferase
- β-oxidation
- metastatic pancreatic ductal adenocarcinoma
- CrAT
- long-chain fatty acid oxidation disorders
- skeletal muscle mitochondria
- heart mitochondria
- Inhibitor
- inhibitor
- inhibit